167 related articles for article (PubMed ID: 24332494)
1. Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer.
Grue-Sørensen G; Liang X; Månsson K; Vedsø P; Dahl Sørensen M; Soor A; Stahlhut M; Bertelsen M; Engell KM; Högberg T
Bioorg Med Chem Lett; 2014 Jan; 24(1):54-60. PubMed ID: 24332494
[TBL] [Abstract][Full Text] [Related]
2. Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
Liang X; Grue-Sørensen G; Månsson K; Vedsø P; Soor A; Stahlhut M; Bertelsen M; Engell KM; Högberg T
Bioorg Med Chem Lett; 2013 Oct; 23(20):5624-9. PubMed ID: 23993332
[TBL] [Abstract][Full Text] [Related]
3. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
4. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
6. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
7. Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.
Woo YR; Lim JH; Jeong SW; Cho DH; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1012-1017. PubMed ID: 28370377
[TBL] [Abstract][Full Text] [Related]
8. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
[TBL] [Abstract][Full Text] [Related]
9. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.
Cozzi SJ; Ogbourne SM; James C; Rebel HG; de Gruijl FR; Ferguson B; Gardner J; Lee TT; Larcher T; Suhrbier A
J Invest Dermatol; 2012 Apr; 132(4):1263-71. PubMed ID: 22189786
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Cytotoxicity against K562 Cells of 3-O-Angeloyl-20-O-acetyl Ingenol, a Derivative of Ingenol Mebutate.
Liu M; Chen F; Yu R; Zhang W; Han M; Liu F; Wu J; Zhao X; Miao J
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548156
[TBL] [Abstract][Full Text] [Related]
11. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
12. Ingenol mebutate: an introduction.
Fallen RS; Gooderham M
Skin Therapy Lett; 2012 Feb; 17(2):1-3. PubMed ID: 22358305
[TBL] [Abstract][Full Text] [Related]
13. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
14. Could ingenol mebutate be useful in managing nonmelanoma skin cancers?
Bhandari PR; Pai VV
Indian J Cancer; 2015; 52(2):249-50. PubMed ID: 26853424
[No Abstract] [Full Text] [Related]
15. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
Abramovits W; Oquendo M; Vincent KD; Gupta AK
Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
[No Abstract] [Full Text] [Related]
16. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
17. Effect of ingenol mebutate on actinic keratosis in a Korean population: A prospective clinical, dermoscopic and histopathological study from a single center.
Kim JS; Woo YR; Kim M; Park HJ
J Dermatol; 2018 Nov; 45(11):1324-1330. PubMed ID: 30260493
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate.
Emmert S; Haenssle HA; Zibert JR; Schön M; Hald A; Hansen MH; Litman T; Schön MP
PLoS One; 2016; 11(9):e0160096. PubMed ID: 27612149
[TBL] [Abstract][Full Text] [Related]
19. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]